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GPR132 is an orphan class A G protein-coupled receptor. It has been proposed to be activated by protons and
to regulate apoptosis, atherosclerosis and inﬂammation, but these results are still preliminary. In the current
work, we designed and screened a focused compound library using a b-arrestin recruitment assay, and
thereby identiﬁed the ﬁrst disclosed surrogate GPR132 agonist 1 with a potency of 3.4 mM. This constitutes
the ﬁrst available pharmacological tool for the in vitro characterization of the orphan receptor GPR132. The
testing of 32 analogs furthermore identiﬁed a number of compounds with lower activity – of which six
were agonists and two were antagonists – that were used to construct preliminary structure–activity
relationships. Docking followed by a molecular dynamics simulation of compound 1 in a structural model
of GPR132 displayed the putative interactions for the key ligand functionalities.Introduction
G protein-coupled receptors (GPCRs) constitute the largest family
of cell surface receptor proteins.1 They are involved in the regu-
lation of a wide range of physiological processes including
vision, metabolism, neurotransmission and inammation,2,3 and
approximately 30% of FDA-approved drugs are thought to target
GPCRs.4,5 More than 800 diﬀerent sequences in the human
genome encode for GPCRs, of which approximately 350 sequences
encode for non-olfactory receptors.6 Their involvement in various
physiological processes has made GPCRs one of the most pursued
target classes in academia as well as industry. GPR132 has been
ascribed several putative endogenous ligands. In 2001, lysophos-
phatidylcholine was proposed7 to be the natural agonist but these
results were later retracted,8 and in 2004 it was shown to function
as an antagonist.9 In 2005, another lipid derivative, 9-hydroxy-10E,
12Z-octadecadienoic acid, was presented as an alternative endog-
enous agonist,10 but this could not be conrmed in another
study.11 Independent analyses have instead provided evidence that
GPR132 functions as a sensor for extracellular pH.9,12 This is in
agreement with a phylogenetic analysis that grouped GPR132 with
the proton-sensing receptors GPR4, GPR65, and GPR68.13cology, Faculty of Health and Medical
vej 162, 2100 Copenhagen, Denmark.
.dk; Tel: +45 35 33 61 62; +45 39 17 96 59
nt of Chemistry, University of Cambridge,
tion (ESI) available. See DOI:
hemistry 2015Surrogate GPR132 ligands were reported by Invitrogen
Discovery Sciences and Amgen in 2009, but without disclosing
their structures.11 The physiological function of GPR132 is still
unknown, although several hypotheses have been presented.
Firstly, studies in this direction found that GPR132 triggers
chemotaxis of monocytic phagolytic cells towards apoptotic cell
remnants14 and promote anti-inammatory responses in
human skin epidermal cells and keratocytes by suppressing
DNA synthesis and freezing specic cell cycle phases.15
Secondly, GPR132 is expressed on macrophages,16 and has been
suggested to be involved in atherosclerotic lesion growth in the
aortic tissue and the coronaries.17 However, later studies display
ambiguous results as the formation of atherosclerosis lesions
was suppressed and promoted by knockout and silencing of the
GPR132 gene, respectively.18,19 Finally, over-expression of
GPR132 has been found to inhibit tyrosine kinases involved in
the activation of BCR/ABL fusion proteins,20 which play a key
role in the oncogenesis and proliferation of some cancers.21
In this article, we now disclose the rst surrogate agonist for
GPR132 with potency in the singlemicro-molar range (Fig. 1, Chart
1). Receptor structure modeling and ligand docking studies
present the putative molecular mechanism of action, which could
contribute to future structure-based optimization towards in vivo
application. The description of therst publically available GPR132
surrogate agonist is an important rst step towards the pharma-
cological and physiological characterization of the receptor.Materials and methods
GPCR-focused compound libraries
We designed focused GPCR screening libraries based on iden-
tication of novel privileged structures, which are core scaﬀoldsRSC Adv., 2015, 5, 48551–48557 | 48551
Fig. 1 Pharmacological characterization of the identiﬁedGPR132 agonist 1. (A) Representative concentration–response curve of agonist 1 on the
human GPR132 receptor. The calculated pEC50 value for 1 is 5.46  0.09 (EC50 ¼ 3.4 mM). Counter screening of 1 (B and C) and the concen-
tration–response curve of ISO on the b2-adrenergic receptor (C). ISO is a b2-adrenergic receptor agonist and has been used as a positive control
in the assay. The calculated pEC50 value for ISO equals 6.97  0.05. Measurements of luminescence (RLU) in response to receptors activation
have been performed in PathHunter b-arrestin recruitment assays, in CHO cell lines expressing human GPR132 (A) or b2-adrenergic receptor (B
and C). All data represent mean  SD from one representative out of ﬁve (A) or two (B and C) independent experiments performed in triplicates.
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View Article Onlinewith known activity at multiple diverse receptor targets.22–24 We
fetched all 62 000 GPCR-active ligands from ChEMBL ver.1425
and identied 50 frequent substructures using Gaston26 that
form parts of existing ligands for several diverse GPCR targets,
e.g. small molecule, peptide and lipid receptors. The design of
focused screening libraries started by querying these “privileged
structures” against the entire Enamine screening compound
collection in Instant JChem.27 More than 50 000 compounds
were exported to Schro¨dinger Maestro,28 prepared with Lig-
Prep29 and physicochemical properties were calculated with
QikProp.9 Filters were applied to remove reactive structural
groups and to enrich the dataset for compounds with desirable
solubility, size and interaction features. Specically the applied
lters were: molecular weight (3–500), rotatable bonds (2–10),
hydrogen bond donors and acceptors (0–5 and 0–10, respec-
tively, but requiring at least one of either), Q log S (>6), Q log P
(<5), FISA (7–330) and number of rings (max 5). The remaining
compounds were clustered with the Maestro script for Canvas
similarity and clustering and 1–3 representative compounds
were handpicked from each cluster. The nal library consisted
of 1600 lead- and drug-like screening compounds specically
selected for likely GPCR-activity.
To allow for library sub-selection based on target binding site
charge, the overall library was divided into 3 sub-libraries con-
taining negatively, neutral and positively charged compounds,
respectively. All compounds were purchased from Enamine
(Kiev, Ukraine) as 10 mL of 10 mM solution in 100% frozen
DMSO plated on 384 well plates. The structure of compound 1
was conrmed by 1H NMR and HPLC-MS (Chart SI2†).
Pharmacological assaying
The G protein signaling pathways of many orphan GPCRs are
still unknown, making second messenger-based assays unsuit-
able for screening for orphan receptor ligands. Thus, the b-
arrestin2 recruitment assay (DiscoveRx)30 was employed in the
screening and the subsequent hit validation. Since recruitment
of b-arrestins constitutes an universal “oﬀ-switch” for GPCRs,
assays based on b-arrestins binding to the activated receptors
should oﬀer the possibility of detecting GPCRs activation
regardless of the routes of G protein signaling. DiscoveRx b-
arrestin recruitment assays have been used previously for48552 | RSC Adv., 2015, 5, 48551–48557identication of endogenous and surrogate ligands of orphan
GPCRs.31,32
24 hours before performing the assay, the PathHunter
eXpress GPR132 or b2-adrenergic receptor (ADRB2) cells were
thawed in 9.5 mL of cell plating reagent 1 or 0, respectively.
Subsequently, 20 mL of cell suspension/well was seeded in a 384-
well plate (Greiner Bio-One) and incubated overnight at 37 C
and 5% CO2. On the day of assaying, the compound libraries
were thawed on a plate shaker at 450 rpm and ligand plates
where prepared with 100 mM compound solution in ligand
buﬀer (Hank's balanced salt solution, 10 mM HEPES, pH 7.4).
Subsequently, 5 mL of the ligand solution was added to each well
of the cell-containing plate. Plates were sealed and incubated
for 90 min at 37 C, followed by 30 min incubation at RT. For
antagonist mode screening, cells were pre-incubated for 30 min
at 37 C with the EC80 of 1 (8.5 mM),33 followed by 60 min
incubation at 37 C with the tested compound. Thereaer, 12.5
mL of PathHunter detection solution (DiscoveRx) was added to
each well and plates were incubated in darkness for 60 min.
Chemiluminescence, indicated as relative luminescence units,
was measured with an EnSpire 2300 Multilabel Reader (Perki-
nElmer, Waltham, MA, USA).
Compounds were screened at 20 mM, in single measure-
ments, with 1% (v/v) nal concentration of DMSO. Hits
(compounds with the activity greater than three times stan-
dard deviations of the assay buﬀer) were subsequently retes-
ted in concentration–response studies. Analogs of 1 were
tested in both agonist and antagonist mode (in the presence
of 8.5 mM of 1) and a cut-oﬀ of 5% and 25%, respectively, was
applied to distinguish active compounds in the agonist and
antagonist screen mode, respectively. The EC80 of agonist for
the antagonist mode screening was chosen as a compromise
between a large assay window (to maximize signal to noise
ratio) and sensitivity to antagonist,33 based on the assumption
that the tested compounds would behave as competitive
antagonists given their structural similarity with compound
1. To increase chances of observing competitive antagonism,
the ligands were tested in their highest soluble concentration
(20 mM).
Curve tting was performed by non-linear regression using
the sigmoidal dose–response equation (variable slope) inThis journal is © The Royal Society of Chemistry 2015
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View Article OnlineGraphPad Prism 6.0 (GraphPad Soware, San Diego, C.A,
USA).
GPR132 homology modeling
The crystal structure34 of the inactive human protease-activated
1 receptor (PAR1; PDB: 3VW7) was selected as the main
template, using the GPCRdb template selection tool.35 The
resolution of the PAR1 structure is 2.20 A˚. The protein sequence
similarity between the target and template receptor is 64% in
the seven trans-membrane helical (7 TM) region. Based on
sequence length and similarity, a second template, the human
chemokine receptor 4 (CXCR4) structure (PDB: 3ODU),36 was
used for the part from the second extracellular loop (ECL2)
spanning between TM5 and the cysteine forming the conserved
disulde bridge to TM3. To improve the GPR132 structure
model for subsequent ligand docking, non-conserved amino
acids within the binding pocket had their rotamers dened
based on an in-house GPCR position-specic rotamer library
that contains rotamers extracted from all published GPCR
crystal structures.37 In this manner, the rotamers could be ne-
tuned for S1x31, L1x35, Y1x39, W2x60, I2x64, T3x28, Y5x40, F5x43, Y6x51,
H6x52, V6x54, K6x58, L7x30, L7x38, and T7x42. The protein sequences
of the chimeric template and target were aligned with
MEGA5.2,38 using the GPCRdb alignments as a reference for the
seven helices.
Modeller9v13 (ref. 39) was applied to build 500 homology
models and the best model was selected based on DOPE score.
The model backbone was assessed by Ramachandran40 plots
(Fig. SI1†) within the PROCHECK41 webserver. The GPR132
model was prepared with the Schro¨dinger Protein Preparation
Wizard,42 including an hydrogen optimization at pH 7 of the
ionizable polar groups using Maestro PROPKA.42
Ligand docking and molecular visualization
Compound 1 was docked with Glide43 in the extra precision
mode, and exible ligand sampling was applied. The partial
charges of the ligands were assigned by Epik44 using the
OPLS_2005 force eld. The van der Waals radii scaling factor
was set to 0.8 and the partial charge cutoﬀ to 0.15. Further
options were set to allow the rotation of hydroxyl hydrogen
atoms in the binding site, enhance the planarity of conjugated
p-systems, and to include the Epik state penalties to the scoring
calculations. Subsequently, QM-Polarized Ligand Docking45
(QPLD) was applied. Jaguar46 performed the partial charge
calculations with the QM estimation level set to accurate (6-
31G*/LACVP* basis set, B3LYP density functional, and “Ultra-
ne” self-consistent eld accuracy level). SiteMap47 was used to
map the GPR132 binding cavity. Residue positions were indexed
with the GPCRdb scheme,48 which corrects for helical bulges
and constrictions. 2D structures were drawn in MarvinSketch49
and 3D structures were visualized using PyMOL.50
Molecular dynamics simulation
The receptor–ligand complex was minimized using the energy
minimization tool in MacroModel51 Schro¨dinger. The TNCG
(Truncated Newton Conjugate Gradient) minimization methodThis journal is © The Royal Society of Chemistry 2015was used with maximum iteration steps set to 5000, and the
convergence gradient to 0.001. Desmond52 was employed to
conduct a molecular dynamics (MD) simulation for 20 ns on the
complex in the predened POPC membrane model. Explicit
water molecules were handled using the simple point charge
model. Constant temperature and pressure were applied at 300
K and 1.01325 bar, respectively. The system was coupled to an
isotropic Berendsen thermo- and barostat, with relaxation set to
1 and 2 ps respectively.Results and discussion
Identication of the rst surrogate GPR132 agonist
Screening of the GPCR-focused libraries against the human
GPR132 receptor yielded a hit (1, Chart 1) with 3.4 mM potency
(Fig. 1A). Compound 1 is racemic and thus one of the enan-
tiomers may have a higher potency than observed for the race-
mate. To evaluate whether the observed increase in
luminescence is GPR132-mediated, 1 was also tested at another
class A GPCR, the b2-adrenergic receptor. Ligand 1 did not
induce b-arrestin recruitment in CHO cells expressing
b2-adrenergic receptor, while the positive control isoproterenol
(ISO) produced a concentration-dependent response with an
EC50 of approximately 100 nM (Fig. 1B and C). Hence, we
concluded that the activity of 1 is not unspecic, but mediated
via GPR132.GPR132 structure model and compound 1 binding mode
To achieve a GPR132 model of suﬃcient quality for ligand
docking, we found that it was necessary to locally replace the
main template (the protease-activated 1 receptor) with alterna-
tive templates. The part of the second extracellular loop (ECL2)
from the conserved cysteine (C45x50) to TM5 is crucial as it acts
as a lid of the binding pocket in many class A GPCRs, and it
oen forms ligand interactions.53 This segment was longer in
the protease-activated 1 receptor (10 instead of 7 residues); thus
the human chemokine receptor 4 (also has 7 residues) was the
most suitable template for modeling this segment. Further-
more, for binding pocket residues not conserved between the
protease-activated 1 receptor and GPR132, we applied rotamers
from the other most homologous receptors. In this way, 29 out
of 36 (81%) side chains within the GPR132 binding cavity
could be dened according to a conserved crystal structure
template. Validation of the GPR132 model in PROCHECK41
showed that 93.5% of the residues are within the optimal
backbone torsion angles and 6.5% are near-optimal (Fig. SI1†).
The docking pose of ligand 1 displayed close shape
complementarity with the GPR132 binding pocket and good
agreement with the receptor hydrophobic and hydrogen
bonding sites (Fig. SI2A–C†). The R- and S-enantiomers
exhibited very similar binding mode. However, the hydrophobic
binding site matched the methyl substituent better for the R-
enantiomer, which was therefore chosen for the further anal-
yses. Five residues displayed hydrogen bond interactions with
the ligand namely Y1x39, D45x52, H4x57, Y6X51, and K6x58. Both
Glide and QPLD resulted in identical outcome. To evaluate theRSC Adv., 2015, 5, 48551–48557 | 48553
Chart 1 Chemical structures of the ﬁrst disclosed GPR132 surrogate agonist 1 and its analogs 2–33. Ag denotes the six analogs 2, 9, 18, 31, 32, and
33 with weak agonistic activity. Ant denotes the two analogs 11 and 12 with weak antagonistic activity. 1 marks the three 1-substituted anthra-
quinone analogs 12, 16, and 29. 2D structures were drawn in MarvinSketch.49
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View Article Onlineaccuracy of our docking procedure, we re-docked the ligands in
the three most homologous GPCR crystal structures; the
protease-activated 1 receptor (PDB: 3VW7),34 the m-opioid
receptor (PDB: 4DKL),54 and the chemokine receptor type 5
(PDB: 4MBS)55 respectively. The docked ligands showed very48554 | RSC Adv., 2015, 5, 48551–48557similar poses as the crystallized with RMSD values of 0.643,
1.306, and 0.270 A˚, respectively (Fig. SI3A–C†).
In our molecular dynamics simulation of the 1 – GPR132
complex, in a membrane and solvent environment, the ligand
remained in the same binding cavity throughout the entire 20This journal is © The Royal Society of Chemistry 2015
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View Article Onlinens simulation (Video SI1†), conrming that the complex is
stable. The observed interactions and their durations are
summarized in Fig. 2. The anthraquinone of 1 appeared to be
occupying a hydrophobic site between TM3-5 that provided p–p
aromatic (residues F3x33 and Y5x39) and hydrophobic (residues
I5x35 and P4x59) contacts (Fig. 2C). The pyridinyl ring formed a
p–p interaction with W2x60 and, together with the methylated
linker; favorable hydrophobic contacts with several aliphatic
residues could be seen (Fig. 2C).
The linker amide group displayed hydrogen bonding to both
Y6x51 and a bridging water molecule to D45x52, a residue position
in the second extracellular loop that oen forms contact with
class A receptor ligands.53 In shorter periods of the simulation,
the bond with Y6x51 was also indirectly formed via a water
molecule (Fig. 2). All active analogs have this amide, indicating
that its interactions could contribute to the stabilization of an
active receptor conformation. The carbonyl oxygen in the amide
linker also displayed a potential indirect interaction to Y5x40
(Fig. 2C). On the other hand, the carbonyl oxygen in the
propionate group presented indirect hydrogen bonding to Y6x51
(Fig. 2C).
The oxygen atom in the 10-position of the anthraquinone
ring displayed three putative water-mediated hydrogen bondFig. 2 (A) Top and (B) side views of a representative binding pose of co
Hydrogen bonds are shown in dashed yellow lines representing the pairin
(grey). The simulation ligand interactions diagram (C) represents a sum
Desmond. All detected hydrogen bonds (grey lines) are represented with
the GPCRdb scheme48 to correct for bulges and constrictions.
This journal is © The Royal Society of Chemistry 2015interactions bridging K6x58, D5x32, and the backbone of L45x54,
respectively. The atom also presented a potential direct inter-
action with Y5x40. The simulation showed that the most
frequent hydrogen bonds were the indirect ones to L45x54 and
D5x32 via bridging water molecules (Fig. 2C). The oxygen in the
9-position presented a direct hydrogen bond interaction with
H4x57 or an indirect one with D45x52 (Fig. 2C). The pyridinyl ring
nitrogen interacted rmly with Y1x39 (Fig. 2). Altogether, six of
the seven polar ligand atoms displayed hydrogen bond inter-
actions, whereof four mainly indirectly via water molecules, and
two directly to the receptor side chains.Preliminary structure–activity relationships of compound 1
analogs
The structures of compound 1 and the 32 tested analogs are
shown in Chart 1. All active analogs have lower potency than 1,
and because of their limited solubility, it was not possible to
produce full concentration–response curves and derive
EC50/IC50 values. Instead, their relatively weak activities are
reported in Table 1 at their maximum soluble concentration,
which was 10 mM or 20 mM, respectively. Six of the analogs,
namely 2, 9, 18, 31, 32 and 33, display weak agonistic activitympound 1 (green), obtained from the molecular dynamics simulation.
gs between the ligand polar groups and the diﬀerent receptor residues
mary of the interactions observed in the simulation obtained from
their corresponding percentages. Residue positions are indexed with
RSC Adv., 2015, 5, 48551–48557 | 48555
Table 1 Maximal eﬀectsa of the active analogsb of 1 at PathHunter
eXpress CHO-K1 cells expressing GPR132
Compound Rel. Emax (%) SEM Conc. (mM) N
1 100 — — 5
2 18 2.9 10 3
9 9 0.1 20 2
18 14 2.8 10 3
31 13 1.0 20 3
32 13 0.2 20 3
33 8 0.3 20 3
a The relative Emax of tested compounds was calculated by dividing the
span of compound response by the span of 1 response in the same
experiment and on the same plate. b Compounds with a relative Emax
higher than 5% were considered as agonists.
RSC Advances Paper
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View Article Onlinewith relative Emax between 8 and 18% at the highest soluble
concentration (10 or 20 mM, Table 1).
Compound 2 is the most similar analog to 1 and also has the
highest activity of the analogs (relative Emax of 18% at 10 mM). It
diﬀers by having a terminal pyrimidine on a trigonal nitrogen
instead of a pyridine on a tetrahedral carbon, which is also the
chiral center in compound 1. Glide docking of compound 2
showed that the hydrogen bond to Y1x39 is lost as this
compound lacks the pyridine nitrogen in the 4-position
(Fig. SI4A†). Compounds 3–5 have a terminal phenyl moiety and
in turn lack the methyl group, indicating that either a hydrogen
bond acceptor in the aryl 4-position or a methyl function could
be benecial for activity. Compounds 9 and 10 contain a
terminal meta- and para-methoxy-phenyl, respectively, on a
linker that is extended by an extra nitrogen or oxygen atom,
respectively, compared to 1. In our docking, the nitrogen in 9
formed a hydrogen bond to the backbone carbonyl of C45x50
(forms a disulde bridge from the second extracellular loop to
the top of TM3), whereas the oxygen in 10 displayed no inter-
action (Fig. SI4B and C†). This provides a hypothesis for the
activity of 9, as opposed to 10. In the nal analogs with agonistic
activity, 31–33, the 1,1-diphenyl group docked into the same site
as the pyridine moiety, not the anthraquinone core, of
compound 1 (Fig. SI4D–F†). In each compound, the propionate
linker showed a hydrogen bond to Y6x51. Only compound 32 was
still able to display hydrogen bonding to K6x58 via the acetamide
terminal group (Fig. SI4D–F†).
Two of the analogs, 11 and 12, display antagonistic activity:
the inhibition of compound 1 is 39–46% at 20 mM (Table 2).
These two compounds have higher similarity to other non-Table 2 Inhibitiona of 1-mediated b-arrestin recruitment in CHO-
GPR132 cells upon incubation with indicated concentrations of
selectedb analogs of 1
Compound Inhibition (%) SEM Conc. (mM) N
11 46 16 20 2
12 39 14 20 2
a The responses have been normalized to ligand buﬀer (100%
inhibition) and 8.5 mM (EC80) of 1 (0% inhibition).
b Compounds with
more than 25% inhibition were considered as antagonists.
48556 | RSC Adv., 2015, 5, 48551–48557antagonist analogs than to each other. Compound 11 is one
of ve analogs, 7–11, which have a linker that is one atom longer
than in compound 1. Moreover, 11 is unique in that it has the
largest terminal substituent, an indole, and lacks a preceding
polar functionality. 12 is one of three 1-substitued anthraqui-
nones (12, 16 and 29). Compared to 16 the ring of 12 is non-
aromatic and positioned on a one atom longer linker. Further-
more, varying linker lengths are seen among both agonistic and
antagonistic analogs; compounds 9, 11, 12, and 18 have linkers
that are between one atom longer and two atoms shorter.
Taken together, the testing of commercially available
analogs has allowed for the derivation of preliminary structure–
activity relationships, that although limited, can serve as a
guide for further lead optimization by custom synthesis.Conclusions
The association of GPR132 with several alternative proposed
physiological ligands and functions warrants the development
of tool compounds that can be used to characterize this
receptor. In this work, we have disclosed the rst surrogate
agonist 1. The analogs tested, and the binding modes and
structure–activity relationships proposed herein, will be valu-
able for future medicinal chemistry optimization of compound
1, as well as mutagenesis of interacting receptor residues.Acknowledgements
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